India Launches First Homegrown H5N1 Vaccine for Poultry

On November 20, 2026, India will officially introduce its first indigenous vaccine against H5N1 avian influenza.

A
Aapla Nagpur Desk
19 Nov 2026, 4:32 PM IST · 2 min read
Source: Poultrymed
India Launches First Homegrown H5N1 Vaccine for Poultry
KEY TAKEAWAYS
1

The vaccine was developed by ICAR-NIHSAD in Bhopal.

2

India has faced over 500 H5N1 outbreaks since 2006.

3

Commercial vaccination against H5N1 is currently prohibited in India.

India is set to make a significant advancement in avian health with the upcoming launch of its first domestically produced vaccine against Highly Pathogenic Avian Influenza (HPAI) H5N1 in chickens. This vaccine, developed by the Indian Council of Agricultural Research–National Institute of High Security Animal Diseases (ICAR-NIHSAD) located in Bhopal, will be officially dedicated to the nation on November 20, 2026, by the Union Minister of Agriculture and Farmers Welfare.

The introduction of this vaccine marks a pivotal moment in the global approach to controlling HPAI, particularly in major poultry-producing regions. However, veterinary officials clarify that this launch signifies a scientific milestone rather than an immediate regulatory approval for widespread vaccination in the field. The inactivated vaccine was created in high-containment biosafety facilities at ICAR-NIHSAD, specifically targeting H5N1 strains prevalent in Indian poultry, thus addressing a critical demand for a commercial vaccine that aligns with the country's endemic viral strains.

Since the first identification of H5N1 in India in 2006, the nation has experienced over 500 outbreaks involving both H5N1 and H5N8 strains. Government evaluations indicate that an uncontrolled epidemic could jeopardize more than 20% of the national poultry population and potentially decrease the country's GDP growth by up to 1.5%. Additionally, there are rising One Health concerns due to spillover detections in mammals and confirmed human cases linked to the local viral clade.

Despite this scientific breakthrough, the use of commercial and emergency vaccination against H5N1 remains strictly prohibited in India. A notable technical aspect for international veterinary experts is that the vaccine developed by ICAR-NIHSAD specifically targets H5N1 clade 2.3.2.1a, which is significantly different from the H5N1 clade 2.3.4.4b, the lineage responsible for severe poultry losses in regions such as Europe, North and South America, and Africa in recent years.

Looking ahead, the introduction of this vaccine could reshape the landscape of poultry health management in India, although the regulatory framework for its use in commercial settings will need to evolve. The upcoming dedication ceremony is expected to attract attention from both national and international stakeholders in the agricultural and veterinary sectors.

💬What did you think of this story?What did you think?

Read Next

India's First Indigenous H5N1 Poultry Vaccine